Clinical Trials
Showing 1166 Clinical Trials-
Randomized Controlled Trial of Intranasal Ketamine vs. Intranasal Midazolam in Individuals With OCD
Start Date: September 2022 Updated: May 2017
New York, New York, USAKetamine
Phase 2
Terminated
-
A Trial of Intranasal Ketamine for the Treatment of Obsessive-Compulsive Disorder
Start Date: September 2022 Updated: May 2017
Belmont, Massachusetts, USAKetamine
Phase 2
Terminated
-
Effectiveness of Ketamine in Malignant Neuropathic Pain Relief
Start Date: September 2022 Updated: July 2017
Hordaland, Norway
Bergen, Hordaland, NorwayKetamine
Phase 3
Withdrawn
-
Ketamine for Treatment-resistant Depression: A Multicentric Clinical Trial in Mexican Population
Start Date: September 2022 Updated: March 2015
DF, Mexico
Mexico City, DF, MexicoKetamine
Phase 2
Unknown status
-
Ketamine for Suicidality in Bipolar Depression
Start Date: September 2022 Updated: March 2020
New York, New York, USAKetamine
Phase 1|Phase 2
Completed
-
Intranasal Ketamine for Acute Traumatic Pain
Start Date: September 2022 Updated: June 2016
Tel-Aviv, IsraelKetamine
Phase 4
Completed
-
Low Dose Ketamine for Management of Acute Severe Pain in the Emergency Department
Start Date: September 2022 Updated: November 2015
Providence, Rhode Island, USAKetamine
Phase 1
Completed
-
Trial of Xyrem for Excessive Daytime Sleepiness and Sleep Disturbance in Parkinson's Disease (PD)
Start Date: September 2022 Updated: May 2009
GHB
Not Applicable
Completed
-
Psilocybin-assisted CBT for Depression
Start Date: September 2022 Updated: February 2022
Los Angeles, California, USAPsilocybin
Early Phase 1
Not yet recruiting
-
Psilocybin in Co-occuring Major Depressive Disorder and Borderline Personality Disorder
Start Date: September 2022 Updated: June 2022
Chicago, Illinois, USAPsilocybin
Phase 2
Not yet recruiting